The clinical role of molecular imaging: Positron emission tomography/computed tomography and (90)yttrium-DOTATOC in the management of medullary thyroid cancer

Thyroid

Volumn 20, Issue 2, 2010, Pages 233-234

  Turker, Omer ^a   Dogan, Ismail ^b  

^a Thyroidology Unit   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; DIHYDROXYPHENYLALANINE F 18; DOTATATE LU 177; DOTATOC GA 68; DOTATOC Y 90; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; GALLIUM 68; HYNIC TOC TC 99M; RADIOPHARMACEUTICAL AGENT; SUCCIMER; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; LETTER; MOLECULAR IMAGING; NECK METASTASIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; HUMANS; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77149176923     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0214     Document Type: Letter

References (7)

1. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612.
2. Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D 2008 Role of PET in medullary thyroid carcinoma. Minerva Endocrinol 33:67-73.
3. Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Valimaki M, Nuutila P 2009 The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 16:255-265.
4. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP 2008 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 49:524-531.
5. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallie E, Barbet J, Goldenberg DM, Chatal JF, Kraeber- Bodere F 2007 Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 92:4590-4597.
6. Czepczynski R, Kosowicz J, Mikoajczak R, Ziemnicka K, Gryczynska M, Sowinski J 2006 New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma. Pol Arch Med Wewn 116:853-860.
7. Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR, Muller-Brand J, Walter MA 2007 Response to [90Yttrium- DOTA]-TOC treatment is associated with longterm survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13:6696-6702.